Generic Name and Formulations:
Glyburide 1.25mg, 2.5mg, 5mg; scored tabs.
Indications for DIABETA:
Adjunct to diet and exercise in type 2 diabetes mellitus.
Initially 2.5–5mg daily with breakfast or first main meal. Elderly or debilitated: initially 1.25mg daily. Increase by 2.5mg at weekly intervals if needed per blood glucose. Maintenance: 1.25–20mg daily in single or divided doses (consider divided doses above 10mg daily); max 20mg daily.
Type 1 diabetes or diabetic ketoacidosis with or without coma. Concomitant bosentan.
Oral hypoglycemic agents may increase risk of cardiovascular mortality. Renal or hepatic impairment. Adrenal or pituitary insufficiency. Stress. Secondary failure may occur with extended therapy. Risk of hemolytic anemia in G6PD deficiency; consider non-sulfonylurea alternative. Monitor urine, fasting blood glucose, and HbA1c levels periodically. Discontinue if jaundice or hepatitis occurs. Sulfonamide allergy. Malnourished. Elderly. Debilitated. Pregnancy (Cat.C): consider using insulin instead. Nursing mothers: not recommended.
Sulfonylurea (2nd generation).
See Contraindications. May be potentiated by NSAIDs, ACEIs, disopyramide, fluoxetine, clarithromycin, coumarin, alcohol, highly protein bound drugs, salicylates, sulfonamides, chloramphenicol, probenecid, MAOIs, β-blockers, oral miconazole (possibly), fluroquinolones. Antagonized by diuretics, steroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, niacin, sympathomimetics, calcium channel blockers, isoniazid. Monitor closely for hypoglycemia with concomitant drugs that affect glucose metabolism and upon withdrawal. May increase cyclosporine levels; monitor and adjust cyclosporine dose. Caution with CYP2C9 inhibitors or inducers (eg, rifampin). May be antagonized by topiramate, colesevelam; administer glyburide ≥4hrs prior to colesevelam. Disulfiram-like reaction with alcohol (rare). Monitor for 2 weeks if transferring from chlorpropamide.
Hypoglycemia, nausea, epigastric fullness, heartburn, allergic skin reactions, photosensitivity, blood dyscrasias; rare: cholestatic jaundice, hepatitis.
Tabs 1.25mg—50; 2.5mg—100; 5mg—100, 1000
Clinical Pain Advisor Articles
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- Low Literacy Self-Management Program for Chronic Pain May Be Effective
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- The Challenge of Compassion in Modern Healthcare Settings
- Republican Opposition to Obamacare: What's Done, What's to Come
- Lowering Default Pill Counts in EMRs May Effectively Reduce Postoperative Opioid Prescription Numbers
- Steps Taken to Increase Use of Electronic Tools in Medicine
- Daily and Retrospective Pain Measurements Comparable in Hip Osteoarthritis